Piramal Pharma Limited (PPLPHARMA.NS)
- Previous Close
206.01 - Open
201.89 - Bid --
- Ask 207.77 x --
- Day's Range
200.60 - 209.40 - 52 Week Range
136.10 - 307.90 - Volume
3,343,606 - Avg. Volume
7,843,443 - Market Cap (intraday)
274.356B - Beta (5Y Monthly) 0.10
- PE Ratio (TTM)
629.61 - EPS (TTM)
0.33 - Earnings Date May 14, 2025
- Forward Dividend & Yield 0.11 (0.05%)
- Ex-Dividend Date Jul 12, 2024
- 1y Target Est
296.00
Piramal Pharma Limited operates as a pharmaceutical company in North America, Europe, Japan, India, and internationally. The company offers a portfolio of pharmaceutical products and services through global development and manufacturing facilities and distribution network. It also operates contract development and manufacturing organization that provides services across the spectrum of the drug life cycle, including discovery, development, and commercial manufacturing of drug substances and products; complex hospital generics business which offers inhalation anesthetics, intrathecal therapy for spasticity management, injectable pain and anesthesia drugs, and other generic and specialty products; and India consumer healthcare business comprising analgesics, skin care, vitamin/mineral supplement, kids' wellness, digestives, women's health, and hygiene and protection. The company was incorporated in 2020 and is based in Mumbai, India.
www.piramalpharma.com6,719
Full Time Employees
March 31
Fiscal Year Ends
Sector
Recent News: PPLPHARMA.NS
View MorePerformance Overview: PPLPHARMA.NS
Trailing total returns as of 5/9/2025, which may include dividends or other distributions. Benchmark is S&P BSE SENSEX (^BSESN) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: PPLPHARMA.NS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: PPLPHARMA.NS
View MoreValuation Measures
Market Cap
272.01B
Enterprise Value
315.34B
Trailing P/E
624.27
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.08
Price/Book (mrq)
3.44
Enterprise Value/Revenue
3.55
Enterprise Value/EBITDA
20.09
Financial Highlights
Profitability and Income Statement
Profit Margin
0.44%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
89.49B
Net Income Avi to Common (ttm)
389M
Diluted EPS (ttm)
0.33
Balance Sheet and Cash Flow
Total Cash (mrq)
4.08B
Total Debt/Equity (mrq)
60.53%
Levered Free Cash Flow (ttm)
--